Stefanie brings a wealth of experience as she joins Inotec AMD following a successful career having held a number of key finance and strategy leadership positions across Gilead, GlaxoSmithKline and AstraZeneca, where she spearheaded transformative initiatives in corporate development, finance transformation, and global commercial strategy. Her tenure in financial excellence and global expansion includes successfully delivering several strategic growth initiatives across highly competitive and complex markets in Europe and US. Her expertise will be instrumental as Inotec AMD continues to expand access with national reimbursement in the US and distribution worldwide.
“We are excited to have Stefanie on board as Inotec AMD’s new CFO,” said Craig Kennedy, CEO of Inotec AMD. “Her strategic acumen, combined with her deep industry knowledge and commitment to making a difference in patient lives, makes her the perfect fit for Inotec AMD. Stefanie will play a key role in navigating our next phase of growth as we expand our presence in key markets.”
“I’m truly honoured to join Inotec AMD’s talented team and look forward to leveraging my experience in supporting the company’s ambitious growth plans as access expands,” said Stefanie. “It is a privilege to join an organisation at the forefront of innovation and with such dedication to patients, with a mission to reshape the standard of care.”
Stefanie holds a Bachelor’s Degree in Molecular Biology and Genetics from Loyola Marymount University and an Executive MBA from Pepperdine University. With an early career as a scientist in oncology research, Stefanie offers a unique perspective, bridging scientific and financial disciplines in support of life sciences innovation.
About Inotec AMD Inotec AMD is a pioneering company dedicated to transforming wound care through innovation and a steadfast mission on continuous topical oxygen therapy. Headquartered in Cambridge, UK, the company has developed advanced wound care products like NATROX O₂, which have been widely recognized for their efficacy and patient benefits. With NATROX O₂’s regulatory approvals in over 25 countries, Inotec AMD continues expanding access to innovative wound care solutions globally.
What is NATROX O₂ Topical Oxygen Therapy NATROX O₂ is a compact, wearable device which generates and delivers a continuous flow of oxygen directly to the wound bed to promote accelerated healing and foster a healthy wound environment. Its non-invasive nature, coupled with its remarkable effectiveness, offers a significant advancement in chronic wound treatment, even allowing patients to be treated from the comfort of home and experience quality of life.
To learn more, explore the website: natroxwoundcare.com.